NCT07232732CompletedPhase 1
A Study of LY3549492 in Healthy Participants and Participants With Overweight or Obesity
A Phase-1, Parallel-Design, Open-Label, Randomized, Multiple-Dose Escalation Study to Investigate the Safety, Tolerability, and Pharmacokinetics of LY3549492 in Healthy Participants With Overweight or Obesity
Source: ClinicalTrials.gov · Last updated 24 Aug 2026
Brief summary (registry, in English)
The purpose of this study is to see how safe and well-tolerated the drug LY3549492 is and how it behaves in the body, when given in multiple doses to healthy people who are overweight or have obesity. Participation in the study will last approximately 8 weeks.
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 120 (actual)
- First submitted
- 14 Nov 2025
- Start date
- 27 Oct 2025
- Primary completion date
- 16 Jul 2026
- Lead sponsor
- Eli Lilly and Company
- Diseases
- Obesity
- NCT number
- NCT07232732
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 120
- From 27 Oct 2025 to the primary completion date, 16 Jul 2026
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Have had any of the following within 6-months prior to screening
- myocardial infarction
- unstable angina
- coronary artery bypass graft
- percutaneous coronary intervention. (Note: diagnostic angiograms are permitted)
- transient ischemic attack
- cerebrovascular accident or decompensated congestive heart failure, or
- New York Health Association Class III or IV heart failure.
- Have had any exposure to glucagon-like peptide-1 (GLP-1) analogs or other related compounds within the 3 months prior to screening
Other illness
- Have obesity induced by endocrine disorders such as Cushing's syndrome or Prader Willi syndrome.
- Have any of the following conditions at screening,
- supine systolic blood pressure of 160 millimeter of mercury (mmHg) or greater
- supine diastolic blood pressure of 100 mmHg or greater, or
- resting pulse rate of greater than 95 beats per minute (bpm) or less than 45 bpm. (Note: white-coat hypertension is excluded; therefore, if a repeated measurement of blood pressure after at least 5 minutes shows values within the range, the participant can be included).
Lab values
- Have serum triglyceride of 5 millimoles per liter (mmol/L) or greater (442 milligrams per deciliter \[mg/dL\]) at screening
Who the study is looking for
- Have a hemoglobin A1c level of less than 6.5 percent (%) at screening.
- Have a body mass index (BMI) of 25.0 to 45.0 kilogram per square meter (kg/m²), inclusive, at screening
- Participants assigned male at birth (AMAB) or participants assigned female at birth (AFAB) who are individual of childbearing potential (INOCBP) Contraceptive use by participants should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Age in the registry: 18 years to 65 years · Sex: All · Accepts healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Fortrea Clinical Research Unit Coordinator of this site? Confirm its status | Dallas | United States | Unknown status |
| Fortrea Clinical Research Unit Coordinator of this site? Confirm its status | Daytona Beach | United States | Unknown status |
| Fortrea Clinical Research Unit Coordinator of this site? Confirm its status | Madison | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.